MoonLake Immunotherapeutics (MLTX) Current Assets (2020 - 2026)

MoonLake Immunotherapeutics' Current Assets history runs 7 years deep, the most recent figure standing at $396.6 million for Q1 2026.

• In Q1 2026, Current Assets fell 21.65% year-over-year to $396.6 million; the TTM figure through Mar 2026 stood at $396.6 million (down 21.65% YoY), while the FY2025 annual figure was $421.7 million, down 11.09% from the prior year.
• Current Assets for Q1 2026 stood at $396.6 million, down from $421.7 million in the prior quarter.
• The five-year high for Current Assets was $553.6 million in Q1 2024, with the low at $66.5 million in Q1 2023.
• The 5-year median for Current Assets is $455.5 million (2025), against an average of $366.8 million.
• The sharpest annual moves came in 2022 and 2023: Current Assets surged 7857.79% in 2022, then plunged 42.75% in 2023.
• MoonLake Immunotherapeutics' Current Assets stood at $76.5 million in 2022, then jumped by 572.01% to $514.2 million in 2023, then decreased by 7.76% to $474.3 million in 2024, then dropped by 11.09% to $421.7 million in 2025, then fell by 5.94% to $396.6 million in 2026.
• Business Quant data shows MLTX's Current Assets at $396.6 million in Q1 2026, $421.7 million in Q4 2025, and $411.2 million in Q3 2025.